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Purpose or Objective: To assess the safety, feasibility and 
efficacy of free-hand intra-operative multi-catheter breast 
implant and peri-operative high-dose rate brachytherapy 
(FHIOMBI-PHDRBT program) in early breast cancer treated by 
breast conservative surgery (BCS). 
 
Material and Methods: Patients with early breast cancer who 
were candidates for BCS and potential accelerated partial 
breast irradiation (APBI) were prospectively enrolled for the 
FHIOMBI-PHDRBT program. Patients suitable for APBI received 
PHDRBT (3.4 Gy BID for 10 in five days). Patients not suitable 
for APBI received PHDRBT as anticipatory boost (3.4 Gy BID 
for 4 in two days) followed by whole breast irradiation (WBI).  
 
Results: From November 2008 to January 2015, a total of 119 
patients were treated and 122 FHIOMBI procedures were 
performed. Median duration of FHIOMBI was 25 minutes. A 
median of 8 catheters (range 4-14) were employed. No 
intraoperative complications were observed. Severe early 
postoperative complications (bleeding) were documented in 2 
patients (1.6%), wound healing complications in 3 (2.4%), and 
infection (mastitis or abscess) in 2 (1.6%). Late mammogram 
follow-up revealed oil cysts in 56% of patients but 
symptomatic fat necrosis in only 2 patients (1.6%). PHDRBT 
was delivered as APBI in 88 patients (74%) and as a boost in 
31 (26%). The median CTV-T was 40.8 cc (range 12.3-160.5), 
median D90 of 3.32 Gy (range 3.11-3.85), median DHI 0.72 
(range 0.48-0.82) median D10 in high-risk skin zone 1.94 Gy 
(range 0.92-3.37). With a median follow-up of 35 months 
(range 5.9-80.9) in the whole group and 37.7 months (range 
7.6-80.9) in APBI patients, no local, elsewhere or regional 
failures were observed, only one distant failure in PHDRBT 
boost was documented. Cosmetic outcomes were evaluated 
in APBI patients as excellent (42.0%), very good (46.0%), fair 
(10.0%) or poor (2.0%). 
 
Conclusion: The FHIOMBI-PHDRBT program does not add 
complications to conservative surgery, it adapts to breast 
size and location of the tumor, fulfilling at the same time 
prescription requirements and constraints. It allows an 
exquisite selection of APBI patients and offers excellent 
results in disease control and cosmetics. It also offers logistic 
advantages as it dramatically shortens the time of local 
treatment and avoids further invasive procedures. 
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Purpose or Objective: To describe early observations of a 
multi-center study utilizing a single fraction of intra-
operative radiation therapy (IORT) using the Xoft® Axxent® 
Electronic Brachytherapy System® (eBx®) immediately 
following surgical resection of early stage breast cancer. 
 
Material and Methods: 727 subjects have been treated at 25 
hospitals. Upon meeting entry criteria, patients underwent 
partial mastectomy. While in the operating room a balloon 
applicator was placed in the lumpectomy cavity and inflated 
with saline (30–75 cc). The skin was closed over the balloon, 
a balloon surface-to-skin distance of >1.0 cm was confirmed, 
and a single fraction of IORT was delivered to the 
lumpectomy cavity. The prescribed dose was 20 Gy at the 
balloon applicator surface; the mean treatment time was 
10.3 minutes. After treatment, the balloon was deflated and 
removed, and skin sutured. 
 
Results: 726 subjects received the prescribed dose of 20 Gy; 
one received 21 Gy. 56 are removed from the primary 
analysis post-IORT due to subsequent whole breast irradiation 
(N=37), positive lymph nodes (N=7), positive surgical margins 
(N=4), re-excision (N=4), inadequate skin bridge (N=2), 
inadequate balloon conformance (N=1), and other (N=4). 
These subjects will be followed for the duration of the study. 
An additional 60 subjects have withdrawn, leaving 667 active 
subjects. The mean patient age is 65 years (44-88). 148 
subjects (20%) had ductal carcinoma in situ, 550 (75%) had 
invasive ductal carcinoma, 28 (5%) were unknown. DCIS 
nuclear grade was high (N=55), intermediate (N=64) and low 
(N=27); 2 were unknown. Invasive cancer was Grade 1-2 in 
465/550 cases. 93% (N=676) had T1 lesions, 7% (N=51) had T2 
lesions. Mean tumor size is 10.53 mm ± 8.3 mm. Mean follow-
up is 336 days (4-1096). Only 125/926 (13.5%) of the reported 
adverse events were Grade 2 or higher. The most frequent 
AEs are seroma (15.4%), breast pain (14.1%), erythema 
(10.7%), and induration (8.5%). Cosmesis was excellent-to-
good in over half (65%) of the cases. There have been six (6) 
deaths (aortic aneurysm; heart attack; pneumonia; liver 
cancer; 2 unknown causes) and only one (1) recurrence 
reported to-date. 
 
Conclusion: IORT using the Xoft System as part of the 
conservative treatment of breast cancer is safe, with low 
morbidity. Early results from this multi-center trial 
demonstrate this short, convenient course of radiation 
therapy for select patients with early stage breast cancer has 
excellent-to-good cosmetic results and a low rate of low-
grade adverse events. 
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Purpose or Objective: Purpose: The study we report is for 
early stage breast cancer and is a multicentre clinical 
investigation of PBI achieved by interstitial HDR 
brachytherapy with intraoperative placement of catheters. 
